Biotech Industry Examiner

Menu
Menu
subscribe now
Search
Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear

Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear

On a cold Tuesday in early January, Amgen quietly made

Draupnir Bio Raises €12 Million to Advance Oral Protein Degraders Targeting Extracellular Proteins

Draupnir Bio Raises €12 Million to Advance Oral Protein Degraders Targeting Extracellular Proteins

Draupnir Bio, a cutting-edge biotechnology company, has successfully raised €12

Biogen’s $5.6 Billion Apellis Deal Is Really a Bet on Kidney Disease

Biogen’s $5.6 Billion Apellis Deal Is Really a Bet on Kidney Disease

Merck’s $6.7 billion Terns deal is really a bet on life after Keytruda

Merck’s $6.7 billion Terns deal is really a bet on life after Keytruda

Biotech’s AI Race Is No Longer About Models. It’s About Infrastructure.

Biotech’s AI Race Is No Longer About Models. It’s About Infrastructure.

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation

The CRISPR safety reset: what Intellia’s lifted FDA hold really means for one-and-done gene editing

The CRISPR safety reset: what Intellia’s lifted FDA hold really means for one-and-done gene editing

MOST POPULAR

News

The FDA wants to “pre-check” factories before the medicine exists
Obesity’s next arms race: staying power, not just weight loss
The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger

Funding

Aging Science

The explainable aging clock regulators might actually like
Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show

Genomics

M&A & Partnerships

Biogen’s $5.6 Billion Apellis Deal Is Really a Bet on Kidney Disease
Merck’s $6.7 billion Terns deal is really a bet on life after Keytruda
Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation
Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top